Activity content starts in:
Industry Webcast
The ELF® Test: A Simple Blood Test to Measure Risk of Progression in Patients With MASHIndustry Webcast Sponsored by Siemens Healthineers; Not for CME/CE Credit
This presentation provides an overview of metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic dysfunction–associated steatohepatitis (MASH), highlighting their high prevalence, often silent progression to advanced fibrosis and cirrhosis, and strong association with cardiometabolic conditions commonly managed in primary care. The Enhanced Liver Fibrosis (ELF®) Test, alongside the Fibrosis-4 (FIB-4) index, can help primary care clinicians routinely evaluate liver fibrosis and assess the likelihood of progression to cirrhosis and liver-related events, thereby informing clinical decision-making.
CME/CE Information
0 Credits - Not for CME/CE Credit
Release Date: 7/22/2026
Expiration Date: 7/22/2026
Topics
Faculty
Nadege Gunn, MD, CPI, DABOM, FAASLD
Learn MoreSupporters and Partners
Industry Sponsor
Siemens Healthineers
Fine Print
The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.